Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycine N-acyltransferase (GLYAT) is a mitochondrial enzyme that catalyzes the conjugation of glycine with acyl-CoA thioesters, predominantly benzoyl-CoA, resulting in the formation of N-acylglycines such as hippuric acid. This reaction is a key step in the phase II detoxification pathway for both endogenous metabolites and xenobiotics, enabling their excretion. GLYAT displays substrate preference for benzoyl-CoA but can conjugate a broad spectrum of acyl-CoAs. Deficiency or genetic variation in GLYAT can impact the metabolism of compounds like benzoic acid and is relevant to disorders such as isovaleric acidemia and risk of toxicity from food preservatives or salicylate drugs.
Detoxification through formation of N-acylglycines, especially conjugating glycine to acyl-CoA thioesters (most notably benzoyl-CoA), facilitating urinary excretion
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycine N-acyltransferase (GLYAT).